GLP-1 receptor agonists may improve NAFLD indirectly by reducing body weight, increasing insulin sensitivity, or directly binding GLP-1 receptor on liver cells. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatotic liver disease.